首页> 外文OA文献 >Metformin represses the pathophysiology of AAA by suppressing the activation of PI3K/AKT/mTOR/autophagy pathway in ApoE−/− mice
【2h】

Metformin represses the pathophysiology of AAA by suppressing the activation of PI3K/AKT/mTOR/autophagy pathway in ApoE−/− mice

机译:通过抑制ApoE - / - 小鼠中的PI3K / AKT / mTOR /自噬途径的激活来抑制AAA的病理生理学抑制AAA的病理生理学

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Abstract Background The protective effect of metformin (MET) on abdominal aortic aneurysm (AAA) has been reported. However, the related mechanism is still poor understood. In this study, we deeply investigated the role of metformin in AAA pathophysiology. Methods Angiotensin II (Ang-II) was used to construct the AAA model in ApoE −/− mice. The related mechanism was explored using Western blot and quantitative real time PCR (qRT-PCR). We also observed the morphological changes in the abdominal aorta and the influence of metformin on biological behaviors of rat abdominal aortic VSMCs. Results The PI3K/AKT/mTOR pathway was activated in aneurysmal wall tissues of AAA patients and rat model. Treatment with metformin inhibited the breakage and preserved the elastin structure of the aorta, the loss of collagen, and the apoptosis of aortic cells. In addition, metformin significantly suppressed the activation of the PI3K/AKT/mToR pathway and decreased the mRNA and protein levels of LC3B and Beclin1, which were induced by Ang-II. Moreover, PI3K inhibitors enhanced the effect of metformin while PI3K agonists largely reversed this effect. Interestingly, the cell proliferation, apoptosis, migration and autophagy of vascular smooth muscle cells (VSMCs) induced by Ang-II were also decreased following metformin treatment. PI3K inhibitors and agonists strengthened and weakened the effects of metformin in VSMCs, respectively. Conclusions Metformin represses the pathophysiology of AAA by inhibiting the activation of PI3K/AKT/mTOR/autophagy pathway. This repression may be useful as a new therapeutic strategy for AAA.
机译:摘要据报道了据报道了二甲双胍(Met)对腹主动脉瘤(AAA)的保护作用。然而,相关机制仍然较差。在这项研究中,我们深入研究了二甲双胍在AAA病理生理学中的作用。方法使用血管紧张素II(Ang-II)在Apoe / - 小鼠中构建AAA模型。使用Western印迹和定量实时PCR(QRT-PCR)探索相关机制。我们还观察到腹主动脉的形态变化以及二甲双胍对大鼠腹主动脉VSMCs生物学行为的影响。结果AAA患者和大鼠模型的动脉瘤壁组织中激活PI3K / AKT / mTOR途径。用二甲双胍治疗抑制破裂并保留了主动脉的弹性蛋白结构,胶原蛋白的丧失和主动脉细胞的凋亡。此外,二甲双胍显着抑制了PI3K / AKT / mTOR途径的激活,并降低了通过Ang-II诱导的LC3B和BECLIN1的mRNA和蛋白质水平。此外,PI3K抑制剂增强了二甲双胍的作用,而PI3K激动剂在很大程度上反转这种效果。有趣的是,在二甲双胍处理后,Ang-II诱导的血管平滑肌细胞(VSMC)的细胞增殖,凋亡,迁移和自噬也降低。 PI3K抑制剂和激动剂分别加强并削弱了二甲双胍在VSMC中的影响。结论二甲双胍通过抑制PI3K / AKT / mTOR /自噬途径的激活来抑制AAA的病理生理学。这种抑制可能是AAA的新治疗策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号